Neuphoria Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Sep 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 29, 2025
NEUP$2.69-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended June 30, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Cash flows from operating activities: | |||
| Net loss | $(369,632) | $(15,492,166) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Share-based compensation | 163,772 | 814,808 | |
| Depreciation and amortization expense | 662,890 | 662,991 | |
| Non-cash rent expense | 114,363 | 113,503 | |
| Change in fair value of accompanying warrant liability | (956,340) | (338,983) | |
| Change in fair value of contingent consideration | 716,654 | (1,868,437) | |
| Effect of foreign currency remeasurement | 242,348 | (27,350) | |
| Changes in assets and liabilities: | |||
| Accounts receivable, non-trade | 114,936 | 299,203 | |
| Prepaid expenses | (453,058) | 338,713 | |
| Accounts payable | (917,663) | 804,371 | |
| Accrued expenses and other current liabilities | 1,486,656 | 277,854 | |
| Operating lease liabilities | (123,304) | (114,147) | |
| Deferred tax liability | (468,427) | (139,173) | |
| Contingent consideration | (133,080) | - | |
| Other non-current liabilities | (2,886) | (11,964) | |
| Net cash provided by (used in) operating activities | 77,229 | (14,680,777) | |
| Cash flows from financing activities: | |||
| Proceeds from the sale of equity, net of subscriptions receivable of $0.1 million and issuance costs of $0.1 million | 1,528,276 | - | |
| Proceeds from the sale of equity, net of issuance costs of $1.3 million | - | 10,111,979 | |
| Proceeds from the sale of accompanying warrant | - | 4,996,815 | |
| Net cash provided by financing activities | 1,528,276 | 15,108,794 | |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | (3,750) | 76,974 | |
| Net increase in cash, cash equivalents, and restricted cash | 1,601,755 | 504,991 | |
| Cash, cash equivalents, and restricted cash, beginning of period | 12,686,935 | 12,181,944 | |
| Cash, cash equivalents, and restricted cash, end of period | $14,288,690 | $12,686,935 | |
| Reconciliation of cash, cash equivalents, and restricted cash: | |||
| Cash and cash equivalents | $14,210,745 | $12,608,109 | |
| Restricted cash | 77,945 | 78,826 | |
| Total cash, cash equivalents, and restricted cash | $14,288,690 | $12,686,935 | |
| Supplemental cash flow data: | |||
| Cash paid for interest expense | $17,433 | $31,516 | |
| Cash paid for income tax expense | $ | - | $51,853 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.